IRADIMED CORP (IRMD) SEC Filings, Sep-Oct 2025

IRADIMED Corporation (IRMD) director reported RSU vesting and conversion. On 10/14/2025, 1,767 restricted stock units converted into 1,767 shares of common stock at $0 (Transaction Code M). Following the transaction, the director directly holds 6,496 shares.

The RSUs were granted on 10/14/2022 under the 2014 Equity Incentive Plan and vest in three equal annual installments beginning 10/14/2023, delivering one share for each unit that vests.

IRadimed Corp (IRMD) CEO, President and Chairman Roger E. Susi reported insider sales on 10/13/2025 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The transactions totaled 5,000 shares across three trades: 3,227 shares at a weighted average $72.16 (range $71.65–$72.50), 1,746 shares at $73.37 (range $72.93–$73.86), and 27 shares at $74.07 (range $74.05–$74.15).

Following these sales, indirect beneficial ownership was reported as 2,337,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust.

Roger E. Susi, who serves as CEO, President, Chairman and is reported as a 10% owner of Iradimed Corp (IRMD), reported sales of company common stock on 10/06/2025 under a Rule 10b5-1 trading plan adopted 6/16/2025. The Form 4 shows a sale of 4,800 shares at a weighted average price of $71.70 and a separate sale of 200 shares at $72.27, for a total of 5,000 shares disposed. The filing also discloses substantial indirect holdings: 2,342,700 shares indirectly held via a trust and other related trusts holding large positions. The reporting person disclaims beneficial ownership of certain shares except for pecuniary interest.

Joe E. Kiani, a director of Iradimed Corporation (IRMD), received a grant of 2,095 restricted stock units (RSUs) on 09/23/2025 under the companys 2023 Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock and the reporting person is shown as directly owning 2,095 shares following the transaction. The RSUs carry a $0 price and vest in three equal annual installments beginning on 09/23/2026, at which time vested units will convert into an equivalent number of common shares. The Form 4 is signed by Joe E. Kiani on 09/25/2025.

Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD) reported a sale of 5,000 shares of the company on 09/23/2025 under a Rule 10b5-1 trading plan adopted on 06/16/2025. The weighted average sale price was $71.2581, with individual trade prices ranging from $70.81 to $71.61. After the transaction the filing reports total beneficial ownership of 2,352,500 shares, held indirectly through family and revocable trusts; two other trust positions of 162,950 and 2,062,500 shares are disclosed. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed and dated 09/24/2025.

Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD), reported sales of common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted 06/16/2025. The filing shows 3,454 shares sold at a weighted average price of $71.0016 and 1,546 shares sold at a weighted average price of $71.8808, executed in multiple trades with price ranges disclosed. After these dispositions, aggregate beneficial ownership reported across related trusts and accounts totals 2,062,500 shares directly and 2,359,046/2,357,500 shares indirectly as stated, with a disclaimer limiting claimed beneficial ownership. The form is signed 09/18/2025.

Form 144 filed for IRADIMED CORP (IRMD) reports a proposed sale of 100,000 shares of common stock through Roth Capital Partners on 09/17/2025 with an aggregate market value of $7,076,000. The filing identifies the securities as held by the Phillip Susi 2008 Dynasty Trust, acquired on 01/01/1992, and indicates 2,362,500 shares were acquired by that trust on that date. The total shares outstanding reported in the filing are 12,720,002. The filer certifies there are no undisclosed material adverse facts known to the seller and states there were no sales in the past three months by the selling person.

Joe E. Kiani, a director of iRadimed Corporation (IRMD), filed an initial Form 3 reporting the event dated 09/02/2025. The filing states that the reporting person does not beneficially own any securities of the issuer as of the filing. The signature on the form is dated 09/10/2025.

IRadimed Corporation (IRMD) amended its annual report describing its business of MRI-compatible medical devices and related risks, operations, and governance. The company highlights a proprietary MRI-safe IV infusion pump system cleared to operate inside MRI rooms up to the 10,000 gauss-line, features such as optional DERS, wireless remote display, an add-on channel, and Masimo SET-based SpO2 monitoring. Management discloses dependence on a limited number of products, a single Florida manufacturing facility, and key-person concentration with Chairman/CEO Roger Susi exerting significant influence. The filing lists material risks including regulatory approvals and FDA inspections, supply-chain and supplier concentration risks, product liability and intellectual property exposure, cybersecurity controls, and competitive pressures. Recent capital projects include purchase of 26 acres in Orlando and ongoing construction of an expanded facility; the company expects to vacate its Winter Springs leased site once the new facility is operational. The filing also details share counts, stock-based compensation reserves and deferred revenue test procedures.